Cabinet Office to Organize Society 5.0 Expo to Showcase Japan’s Advanced Technologies and Achievements
14.7.2021 09:00:00 EEST | Business Wire | Press release
The Government of Japan’s Cabinet Office announced that it will organize the Society 5.0 Expo jointly with the Japan Agency for Marine-Earth Science and Technology (JAMSTEC) from 15 July at TOKYO SKYTREE TOWN® in Tokyo, Japan. This is expected to be Japan’s first major expo to focus on Society 5.0. The expo will also be viewable online with multilingual explanations for the global audience.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210713006253/en/
[From upper-left] SHINKAI 6500, HAYABUSA2, Wearable Cyborg, Active scope camera for rescue [From lower-left] Ultra-thin and flexible tough polymer, Rescue robot, Small synthetic-aperture radar satellite (SAR), Communication robot, Flying car, Level-3 autonomous vehicle (Photo: Business Wire)
The expo will showcase the Society 5.0 concept proposed by the Japanese government as a highly desirable future society. The concept envisions the creation of a human-centered society in which all industries and other areas of society adopt AI, IoT, robots, big data and other innovative technologies to overcome critical challenges. The Cabinet Office’s 6th Science, Technology and Innovation Basic Plan covering fiscal 2021 to 2025 sets forth the direction of science, technology and innovation policies to secure sustainability, resilience and the well-being of diverse individuals.
The expo will present achievements being realized through national projects focused on increasing innovation in society, including the cross-ministerial strategic innovation promotion program (SIP) and the ImPACT program for stimulating high-risk, high-impact R&D. Japan’s scientific and technological aspirations will be conveyed through numerous displays of advanced technologies.
Specifically, some 50 leading Japanese companies, universities and organizations will exhibit approximately 200 products and research achievements that are expected to contribute not only to Society 5.0 but also the UN’s Sustainable Development Goals. The exhibits will cover fields such as mobility, healthcare and caregiving, manufacturing, agriculture, food, disaster prevention and energy, including:
- Asteroid-explorer Hayabusa2’s returned capsule
- Full-scale model of SHINKAI 6500 submersible piloted to 6,500 meters undersea
- SkyDrive flying car
- Honda Legend Level-3 autonomous vehicle with high-definition 3D mapping
- Model of small synthetic-aperture radar satellite system for on-demand launches and instant observation
- HAL wearable cyborg that transmits brain signals to human muscles for assistance with physical functions
- Disaster-prevention systems for heavy rain and tornado forecasting and ICT-based information sharing
- Smart agriculture technology, such as an automated water supply and drainage system
International viewers will be welcome to enjoy the many exhibits viewable online via mobile devices and PCs, supported with explanations available in a number of languages. The organizers will be pleased to present the virtual exhibition as an opportunity for the global community to learn more about Japan’s forward-looking Society 5.0 concept.
Exhibits will be grouped under the follow themes:
Stage 1 Prologue
The opening theme will present a full-scale model of the SHINKAI 6500 research submersible and a Dagik Earth three-dimensional digital globe, etc. Satellite-based technologies that are being deployed on a practical working basis in various sectors also will be introduced.
Stage 2 Science Frontiers—Space and Ocean
Exhibits of Japan's world-class space-exploration technology will include models of the International Space Station, the "Kibo" Japanese Experiment Module, a full-scale rocket engine, and the Hayabusa2 return capsule.
Exhibits of Japan’s ocean exploration and environmental-simulation technology will include autonomous underwater vehicles for exploring hydrothermal vents and ocean-floor resources and advanced solutions for ocean research.
Stage 3 5.0 Society of the Future
Science and technologies developed through Japan’s SIP and ImPACT programs and how they will help to enhance life in five areas: 1) 100-year lifespans, 2) Mobility and social interaction, 3) Infrastructure for more resilient and safer life, 4) Human- and earth-friendly lifestyles and 5) Advanced manufacturing. Exhibits will include automated solutions such as robots, vehicles and drones, disaster-prevention systems such as AI for infrastructure inspections, robotic industrial borescopes, next-generation energy and resources such as ammonia fuel and ocean-floor minerals, and advanced materials such as synthetic spider silk and strong but flexible ultra-thin polymers.
Stage 4 Trajectory toward Society 5.0
The evolution of human civilization will be presented through videos and other visuals portraying Society 1.0 (hunting & gathering), 2.0 (agriculture), 3.0 (industry) and 4.0 (information) as well as 5.0 (at TOKYO SKYTREE® Tembo Galleria, the closest point to space in Tokyo).
Stage 5 Society 5.0 Theater
Films from the Japan Aerospace Exploration Agency (JAXA) and JAMSTEC will be aired. Also, researchers and experts will give presentations about science, oceans, disaster prevention and ICT for advanced technology and innovation.
Please download official images from here.
Outline of Society 5.0 Expo
|
Organizers |
Cabinet Office and Japan Agency for Marine-Earth Science and Technology (JAMSTEC) |
|
|
Venue |
Exhibition areas within TOKYO SKYTREE TOWN |
|
|
|
- Pavilion at TOKYO SKYTREE TOWN Sky Arena (4F) |
|
|
|
- TOKYO SKYTREE TOWN Solamachi Square (1F) |
|
|
|
- TOKYO SKYTREE Group Floor (1F) |
|
|
|
- TOKYO SKYTREE Tembo Galleria |
|
|
|
- TOKYO SKYTREE TOWN campus of Chiba Institute of Technology |
|
|
|
|
|
|
Dates |
15 July to 5 September 2021 |
|
|
|
- Physical exhibitions by enterprises (15 July to 19 July) |
|
|
|
- Physical exhibitions by other organizations (15 July to 28 July) |
|
|
|
- Sub-exhibition by posters and videos (15 July to 5 September) |
|
|
|
- Virtual exhibition (17 July to 5 September) with multi-language explanations
|
|
|
Admission |
Free (Admission to sub-exhibition by ticket, sold at TOKYO SKYTREE Tembo Galleria) |
|
|
Exhibitors and partners |
Please refer to the list on the official website |
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210713006253/en/
Contact information
Society 5.0 media inquiries
Weber Shandwick
Mayuko Harada (+81-90-9006-4968)
Rina Uesugi (+81-90-2280-0041)
E-mail: society5.0expo@webershandwick.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 20:52:00 EEST | Press release
International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he has served as pro bono counsel to five Nobel Peace Prize laureates. The New York Times has referred to him as "The Extractor" for his work freeing political prisoners worldwide. Genser's decision to support Yim Leak's team comes as the businessman faces an asset freeze exceeding 20 billion baht (more than U
Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 18:38:00 EEST | Press release
Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli ® (Relacorilant)18.9.2026 15:00:00 EEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu ® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 15:00:00 EEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at the 2025 European Society for Medical Oncology (#ESMO25) Congress and subsequently published in The New England Journal of Medicine. The recommendation will now be reviewed by the European Commission, which has the authority to grant marketing authorizations for medicines in the EU. In DES
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca ® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 13:58:00 EEST | Press release
Alfasigma S.p.A, a global pharmaceutical company with a focus on innovation in rare disease and specialty care in areas where there is significant unmet patient need, today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion for Jyseleca® (filgotinib), an oral, once-daily JAK1 preferential inhibitor, for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy. Following this positive opinion, the application is now referred to the European Commission (EC) for final action. The EC’s decision is expected in the next weeks. “At present, half of people living with axSpA fail to adequately respond to treatment, leaving them with years of preventable struggle with persistent pain and other impactful symptoms,” said Daniele D'Ambrosio, Chief Development Officer, Alfasigma. “This
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom